)
About Us
Driven by Our Promise
CSL Behring is a global biotechnology leader, driven by our promise to save and improve lives. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We see significant unmet needs in transplantation and are committed to delivering innovative solutions to address them.
Investment in our R&D
-
US $3.3 billion
in R&D investments in the last 5 years (incl. Seqirus)
-
>1,700
research and development employees
-
40 Countries
with CSL operations serving patients in 60+ countries
Commitment to Innovation
CSL Behring’s commitment to innovation is reflected in our R&D focus across three major areas including plasma therapies, recombinant proteins, and gene therapy. Additionally, our heritage and knowledge in other therapeutic areas such as Immunology and Haematology provides foundational expertise that can be leveraged in transplantation.
Learn more at CSLBehring.com